|By Business Wire||
|February 24, 2014 09:09 AM EST||
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company’s Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February 25-27, 2014. Dr. Brown will chair the main conference plenary session of keynote presentations addressing drug delivery systems for peptides and oligonucleotides; give a presentation titled, “Physical and Chemical Characterization of LNP Formulations of Oligonucleotides vs. Biological Activities;” and participate as a panel member discussing delivery approaches and challenges on Thursday, February 27, 2014.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.